J.P. Morgan analyst Anupam Rama has maintained their bullish stance on SRPT stock, giving a Buy rating today.
Anupam Rama has given his Buy rating due to a combination of factors including the promising long-term potential of Sarepta Therapeutics’ Elevidys product and the company’s expanding pipeline. The recent earnings report for the fourth quarter of 2024 did not reveal any unexpected changes, as the company had already provided guidance at a prior healthcare conference.
Rama anticipates that the company’s 2025 revenue guidance, projected between $2.9 billion and $3.1 billion, is achievable and potentially surpassable. Additionally, the expected data release for SRP-9003 in the first half of 2025 and the planned Biologics License Application submission later that year contribute to the positive outlook. The focus on Arrowhead programs further supports the optimistic view on Sarepta’s future growth prospects.
In another report released today, Morgan Stanley also reiterated a Buy rating on the stock with a $196.00 price target.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com